Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 541400 | NSE Symbol : ZIMLAB | ISIN : INE518E01015 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
14-May-2025	20-May-2025	Accounts	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve Audited financial results for the quarter and year ended 31st March 2025
28-Apr-2025	28-Apr-2025	Change in Auditors	In compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you about the outcome of the Board Meeting held on 28/04/2025
28-Mar-2025	28-Mar-2025	Change in Directors	Disclosure under Regulation 30 - Change in management Disclosure under Regulation 30 - Acquisition Disclosure under Regulation 30 - Appointment of Secretarial Auditor
03-Feb-2025	10-Feb-2025	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December 2024. In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia, considered and approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2024. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed herewith. The Board Meeting commenced at 03:00 p.m. (IST) and concluded at 07:15 p.m.(IST). (As Per Bse Announcement Dated on 10.02.2025)
04-Nov-2024	09-Nov-2024	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Saturday 09th November 2024 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2024. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Tuesday the 01st October 2024 to Monday the 11th November 2024 (both days inclusive). In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved : 1. Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30th September, 2024. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed herewith. 2. Changes in the Senior Management of the Company : a. Categorization of Dr. Chandrashekhar Mainde, Technical Director as the Senior Management Personnel of the Company. b. Categorization of Dr. Uttam Kedar, Assistant Vice President - R&D as the Senior Management Personnel of the Company. The Board Meeting commenced at 03:00 p.m. and concluded at 06:15 p.m. (As Per BSE Announcement Dated on: 09/11/2024)
27-Jul-2024	03-Aug-2024	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2024 inter alia to consider and approve consideration and approval of unaudited financial results (standalone and consolidated) for the quarter ended 30.06.2024. In continuation to the above as per SEBI (PIT) Regulations 2015 and Companys Code of Conduct the trading window for dealing with the securities of the Company is closed from 01.07.2024 to 05.08.2024 (both days inclusive). In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved : 1. Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30th June, 2024. 2. Appointment of Protiviti India Member Private Limited as Internal Auditors of the Company for the F.Y. 2024-25. 3. Investment of upto Euro 1,53,000 in the equity shares of SIA ZIM Laboratories Limited, wholly owned subsidiary of the Company. 4. Incorporation of a Subsidiary of ZIM Laboratories FZE, Sharjah (wholly owned subsidiary of the Company). Post investment, the newly incorporated company would be a step-down subsidiary of the Company. Kindly take the intimation on record. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board in its meeting held on 03rd August 2024 have approved the following: 1. Investment of up to Euro 1,53,000 in equity shares of SIA ZIM Laboratories Limited, WOS 2. Incorporation of subsidiary of ZIM Laboratories FZE (WOS). Post investment the newly incorporated subsidiary will be the step-down subsidiary of the Company (As Per BSE Announcement dated on 03.08.2024)
06-May-2024	13-May-2024	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 inter alia to consider and approve i) the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March 2024. ii) the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March 2024 (prepared pursuant to Regulation 33 of SEBI (LODR) Regulations 2015). In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report of Trading by Insiders the trading window for dealing with securities of the Company is closed from Monday 01st April 2024 to Wednesday 15th May 2024 (both days inclusive). In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved: 1) the Financial Results and Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31.03.2024. Walker Chandiok & Co LLP, Chartered Accountants, the Statutory Auditors of the Company have issued auditor''s report with an unmodified opinion on the financial results for the year ended 31.03.2024 which is enclosed herewith. 2)Investment of upto Rs. 40 Lakhs in the equity shares of SIA ZIM Laboratories Limited, wholly owned subsidiary of the Company. 3)Investment of upto Rs. 02.00 crores in equity shares of ZIMTAS Pty Ltd., subsidiary of the Company. The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular dated 13.07.2023 are also enclosed as Annexure I & Annexure II. Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Acquisition The Board of Directors in their meeting held today has inter-alia considered and approved the financial results and audited financial statements (Standalone and Consolidated) of the Company for the year ended 31st March, 2024. (As Per BSE Announcement Dated on 13/05/2024)
22-Jan-2024	29-Jan-2024	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2024 inter alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December 2023. This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2023. Copy of unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. The Board Meeting commenced at 02:00 p.m. and concluded at 04:00 p.m. In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at their meeting held on Monday 29th January, 2024 approved appointment of Ms. Yuti Nagarkar, Practicing Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for the F.Y. 2023-24 (As Per BSE Announcement Dated on 29/01/2024) Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015, please find enclosed copy of newspaper publication regarding financial results for the quarter and nine months ended 31.12.2023. (As Per BSE Announcement Dated on 30/01/2024)
20-Dec-2023	23-Dec-2023	Employee Stock Option	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/12/2023 inter alia to consider and approve the ZIM Laboratories Employee Stock Option Scheme 2023 (ESOS 2023/ Scheme) pursuant to the provisions of Section 62(1)(b) other applicable provisions if any of the Companies Act 2013 read with rules framed thereunder and the relevant provisions of Regulation 6 of the Securities and Exchange Board of India (Share Based Employee Benefits & Sweat Equity) Regulations 2021 subject to the approval of shareholders of the Company by way of special resolution Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors in their meeting held today have inter-alia approved the 'ZIM Laboratories Employee Stock Option Scheme 2023' ('ESOS 2023'/ 'Scheme') pursuant to the provisions of Section 62(1)(b), other applicable provisions, if any, of the Companies Act, 2013 read with rules framed thereunder, and the relevant provisions of Regulation 6 of the Securities and Exchange Board of India (SBEB) Regulations, 2021, subject to the approval of shareholders of the Company by way of special resolution. The requisite disclosure pertaining to above as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, is enclosed herewith. The Board Meeting commenced at 01:00 p.m. and concluded at 03:20 p.m. (As Per BSE Announcement dated on 23.12.2023)
21-Oct-2023	01-Nov-2023	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Wednesday 01st November 2023 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2023. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Sunday the 01st October 2023 to Friday the 03rd November 2023 (both days inclusive). This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30th September, 2023. Copy of unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. The Board Meeting commenced at 06:00 p.m. and concluded at 07:30 p.m. This is to inform you that the Board of Directors in their meeting held today have inter alia considered and approved unaudited Financial Results (Consolidate and Standalone) for quarter and half year ended 30.09.2023. The copy of unaudited financial results along with Limited Review Report is enclosed. (As per BSE Announcement Dated on 01/11/2023)
05-Aug-2023	14-Aug-2023	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2023. This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30th June, 2023. Copy of the unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30th June, 2023. (As Per BSE Announcement Dated on 14.08.2023)
28-Jun-2023	27-Jun-2023	Acquisitions	Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors in their meeting held on 27th June, 2023, have considered and approved the following: a. Investment of AUD 9,900 (Australian Dollars) in an Australian Company namely ZIMTAS Pty. Ltd. b. Incorporation of a subsidiary in UAE by one of the Wholly owned Subsidiaries of the Company.
16-Jun-2023	16-Jun-2023	AGM	Pursuant to Regulations 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors in their meeting held on 16th June, 2023, have decided that the Register of Members and the Share Transfer Book of the Company will remain closed from Tuesday, 04th July, 2023 till Monday, 10th July, 2023 (both days inclusive) for the purpose of Annual General Meeting.
10-May-2023	19-May-2023	Accounts	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2023 inter alia to consider and approve a) consider and approve the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March 2023. b) consider and approve the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March 2023 (prepared pursuant to Regulation 33 of SEBI (LODR) Regulations 2015). In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report of Trading by Insiders the trading window for dealing with securities of the Company is closed from Saturday 01st April 2023 to Sunday the 21st May 2023 (both days inclusive). In terms of Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved: 1) the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March, 2023. 2) the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March, 2023 (prepared pursuant to SEBI (LODR) Regulations, 2015). Walker Chandiok & Co LLP, Chartered Accountants, the Statutory Auditors of the Company have issued auditor''s report with an unmodified opinion on the financial results for the year ended 31.03.2023. (As Per BSE Announcement Dated on 19.05.2023)
25-Jan-2023	03-Feb-2023	Quarterly Results	Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Friday the 03rd February 2023 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December 2022. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct to regulate monitor and report trading by Insiders the trading window for dealing with securities of the Company is closed from Sunday the 01st January 2023 to Sunday the 05th February 2023 (both days inclusive). This is to inform you that the Board of Directors at its meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2022. Copy of Unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditor of the Company is enclosed. (As Per BSE Announcement Dated on 03/02/2023)

1 2

LOGIN HERE

Zim Laboratories Ltd

Board Meeting